1. Product Introduction
Pidotimod Impurity 30 (CAS 538-75-0), chemically identified as N,N′-Dicyclohexylcarbodiimide (DCC), is a carbodiimide compound relevant to pharmaceutical impurity research, process-related impurity analysis, organic synthesis, and pharmaceutical quality control.
DCC is widely used as a coupling reagent in organic synthesis, particularly for the activation of carboxylic acids and the formation of amide and ester bonds. In pharmaceutical manufacturing research, carbodiimide reagents may be investigated as potential process-related impurities when they are used during the synthesis of active pharmaceutical ingredients or intermediates.
Under the supplier-specific designation Pidotimod Impurity 30, this compound can be used as a reference material for developing analytical methods, investigating potential reagent residues, and evaluating impurity control strategies associated with relevant pidotimod synthesis processes.
In pharmaceutical analytical research, Pidotimod Impurity 30 may support HPLC method development, LC-MS analysis, impurity identification, analytical method validation, and process-related impurity profiling. Its applicability depends on the actual manufacturing route and the analytical objectives of the study.
Pidotimod Impurity 30, 98% is intended for laboratory research and analytical method development. Researchers should verify its identity, purity, and suitability for use as an analytical reference material through the product-specific Certificate of Analysis (COA).
2. Chemical and Analytical Principle
Pidotimod Impurity 30 is chemically identified as N,N′-Dicyclohexylcarbodiimide, a compound containing the reactive carbodiimide functional group (–N=C=N–).
Its relevance to pharmaceutical impurity research is associated with its potential use as a synthetic reagent and the need to monitor residual process chemicals in pharmaceutical intermediates or final products.
2.1 Process-Related Impurity Formation
DCC is commonly employed to activate carboxylic acids during amide bond formation.
General Reaction:
R–COOH + R′–NH₂ + DCC → R–CONH–R′ + DCU
Where:
- R–COOH: Carboxylic acid substrate
- R′–NH₂: Amine-containing substrate
- DCC: N,N′-Dicyclohexylcarbodiimide
- DCU: N,N′-Dicyclohexylurea
During synthesis, unreacted DCC may remain in a reaction mixture if the coupling reagent is not fully consumed.
If DCC is used in a relevant pharmaceutical manufacturing process, residual DCC may require evaluation as a potential process-related impurity.
Important: The presence of DCC in pidotimod products cannot be assumed solely from the designation Pidotimod Impurity 30. Its relevance must be established from the actual synthesis route and process impurity assessment.
2.2 Chromatographic Impurity Analysis
Pidotimod Impurity 30 may be investigated using chromatographic techniques such as HPLC and LC-MS.
These analytical methods can help researchers evaluate the identity and concentration of process-related compounds in pharmaceutical samples.
Analytical approaches include:
- HPLC method development
- LC-MS-based compound identification
- Chromatographic separation optimization
- Impurity retention behavior studies
- Quantitative analysis of residual synthetic reagents
The selection of chromatographic conditions depends on the sample matrix, detection method, compound stability, and required analytical sensitivity.
2.3 Analytical Method Validation
When used as a qualified reference material, Pidotimod Impurity 30 may support the development and validation of impurity testing procedures.
Relevant analytical parameters include:
- Specificity and selectivity
- Linearity and analytical range
- Accuracy and recovery
- Precision and repeatability
- Limit of detection (LOD)
- Limit of quantification (LOQ)
- Solution stability
Method validation should follow the applicable analytical requirements and the intended use of the method.
3. Key Research Applications
3.1 Pharmaceutical Impurity Identification and Profiling
Pidotimod Impurity 30 can be investigated as a potential process-related compound in pharmaceutical impurity studies involving manufacturing routes where DCC is used.
Impurity profiling helps researchers identify and characterize chemical substances that may originate from starting materials, synthetic reagents, reaction intermediates, or manufacturing processes.
Applications include:
- Identification of potential process-related impurities
- Pharmaceutical impurity profiling
- Investigation of residual coupling reagents
- Characterization of synthetic process impurities
- Development of impurity control strategies
When DCC is used during pharmaceutical synthesis, analytical monitoring may be necessary to evaluate its residual concentration.
Pidotimod Impurity 30 can therefore serve as a research material for investigating the chromatographic behavior and analytical identification of DCC in relevant pharmaceutical matrices.
3.2 HPLC and LC-MS Analytical Method Development
Pidotimod Impurity 30 is relevant to chromatographic method development for detecting and measuring DCC in pharmaceutical research samples.
Analytical method development requires suitable separation, detection sensitivity, and reliable identification of the target compound.
Applications include:
- HPLC impurity separation method development
- LC-MS identification of process-related compounds
- Chromatographic retention behavior evaluation
- Optimization of analytical detection conditions
- Development of quantitative impurity assays
Researchers may use the compound to evaluate chromatographic selectivity and establish appropriate detection conditions.
The analytical method should be optimized to distinguish DCC from the active pharmaceutical ingredient, related substances, and other process-derived components.
3.3 Pharmaceutical Process Development and Quality Control
Pidotimod Impurity 30 may support pharmaceutical process research involving the control of residual carbodiimide reagents.
Process-related impurity control is an important component of pharmaceutical manufacturing development and quality assessment.
Applications include:
- Investigation of residual synthetic reagents
- Evaluation of impurity removal during purification
- Pharmaceutical process optimization
- Development of in-process analytical methods
- Research on impurity control and quality specifications
When DCC is part of a synthetic route, its removal may be evaluated through reaction optimization, extraction, crystallization, or other purification procedures.
Analytical testing can help determine whether the selected purification strategy adequately controls residual reagent levels.
3.4 Pharmaceutical Reference Material and Method Validation Research
Pidotimod Impurity 30 may be used in analytical method validation and reference material qualification studies when its identity and purity are appropriately established.
Reliable reference materials are important for evaluating analytical method performance and supporting quantitative impurity measurements.
Applications include:
- Preparation of analytical calibration solutions
- Evaluation of chromatographic method specificity
- Recovery and accuracy studies
- Analytical precision assessment
- Development of impurity quantification procedures
For quantitative applications, researchers should use the assay value and analytical characterization provided in the product-specific COA.
A product labeled 98% purity should not automatically be considered a certified reference standard unless the supplier provides the necessary certification and supporting documentation.
4. Advantages
- Defined Chemical Identity: Corresponds to N,N′-Dicyclohexylcarbodiimide, CAS 538-75-0, with a molecular formula of C₁₃H₂₂N₂.
- Relevant to Process Impurity Research: Suitable for investigating residual carbodiimide coupling reagents in applicable pharmaceutical synthesis processes.
- Supports Analytical Method Development: Can be evaluated in HPLC, LC-MS, and other analytical workflows.
- Useful for Impurity Profiling: Provides a compound for studying chromatographic behavior and potential process-related impurities.
- Applicable to Pharmaceutical Quality Research: Supports research involving impurity identification, process optimization, and analytical quality control.
- Supports Method Validation: May be used in calibration, recovery, precision, and specificity studies when appropriately qualified.
- 98% Purity Grade: Provides a defined research material, with actual purity and impurity specifications subject to verification through the product-specific COA.
5. Storage & Handling
- Store according to the product label and Safety Data Sheet (SDS).
- Keep the container tightly closed and protect the compound from moisture.
- Avoid unnecessary exposure to humid conditions because carbodiimides can undergo hydrolysis.
- Follow the supplier's recommended storage temperature and environmental requirements.
- Handle the compound in an appropriately ventilated laboratory environment.
- Wear chemical-resistant gloves, protective clothing, and suitable eye protection.
- Avoid inhalation of dust and direct contact with skin or eyes.
- Use clean analytical equipment to prevent contamination during reference solution preparation.
- Dispose of chemical waste according to institutional and applicable regulatory requirements.
Important: DCC is a recognized skin sensitizer and can cause allergic reactions following exposure. Appropriate precautions are required to minimize inhalation and skin-contact hazards.
For analytical applications, stock solution stability and storage conditions should be experimentally verified before routine use.
6. Research Areas
- Pharmaceutical Analytical Chemistry: Identification, separation, and quantification of process-related impurities.
- Pharmaceutical Quality Control: Development of impurity testing methods and evaluation of analytical specifications.
- Pharmaceutical Process Chemistry: Investigation of residual coupling reagents and process impurity control.
- Chromatography and Mass Spectrometry: HPLC, LC-MS, and chromatographic method optimization.
- Medicinal Chemistry: Research involving synthetic intermediates, coupling reagents, and pharmaceutical impurity formation.
- Analytical Method Validation: Evaluation of specificity, accuracy, precision, linearity, and detection limits.
- Reference Material Research: Qualification and characterization of analytical materials for pharmaceutical research.
Q1. What is Pidotimod Impurity 30, CAS 538-75-0?
Pidotimod Impurity 30 is a supplier-specific designation associated with N,N′-Dicyclohexylcarbodiimide (DCC), CAS 538-75-0. DCC is a carbodiimide coupling reagent used in organic and pharmaceutical synthesis.
Q2. What is the molecular formula and molecular weight of Pidotimod Impurity 30?
The molecular formula is C₁₃H₂₂N₂, and the molecular weight is approximately 206.33 g/mol. These values correspond to DCC, CAS 538-75-0.
Q3. Is Pidotimod Impurity 30 the same as DCC?
Under the supplier-specific designation associating Pidotimod Impurity 30 with CAS 538-75-0, yes. However, impurity numbering is not universally standardized, so the CAS number and chemical structure should be confirmed when comparing products from different suppliers.
Q4. What is Pidotimod Impurity 30 used for?
It may be used in pharmaceutical impurity identification, chromatographic method development, process-related impurity research, and analytical method validation.
Q5. Is Pidotimod Impurity 30 a degradation product of pidotimod?
It should not automatically be classified as a degradation product. DCC is a synthetic coupling reagent, and its potential presence in a pharmaceutical sample would depend on the manufacturing route and processing conditions.
Q6. Can Pidotimod Impurity 30 be analyzed by HPLC?
Yes. HPLC may be used to investigate the chromatographic behavior and concentration of DCC. Method suitability must be established for the intended sample matrix.
Q7. Can Pidotimod Impurity 30 be analyzed using LC-MS?
Yes. LC-MS may support compound identification and impurity analysis. Suitable ionization conditions, chromatographic separation, and analytical parameters should be validated.
Q8. What does Pidotimod Impurity 30, 98% mean?
The 98% designation indicates the stated product purity. The actual assay, analytical method, and impurity profile should be verified using the product-specific Certificate of Analysis.
Q9. Can Pidotimod Impurity 30 be used as a pharmaceutical reference standard?
It may be used as a laboratory analytical reference material when appropriately characterized and qualified. A 98% research-grade product should not automatically be treated as a certified pharmaceutical reference standard.
Q10. How should Pidotimod Impurity 30 be stored?
Store according to the product-specific SDS and label. For DCC, refrigerated storage at 0–10°C, protection from moisture, and storage under inert gas are specified for certain commercial grades.